Citigroup
AMLX icon

Citigroup’s Amylyx Pharmaceuticals AMLX Stock Holding History

Citigroup’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-71,700
Closed -$1.06M – 5625
2023
Q4 		$1.06M Buy
71,700
+13,500
+23% +$207K ﹤0.01% 2780
2023
Q3 		$1.07M Sell
58,200
-2,500
-4% -$52.9K ﹤0.01% 2454
2023
Q2 		$1.31M Buy
60,700
+30,700
+102% +$829K ﹤0.01% 2617
2023
Q1 		$880K Sell
30,000
-23,100
-44% -$802K ﹤0.01% 2663
2022
Q4 		$1.96M Sell
53,100
-65,800
-55% -$2.34M ﹤0.01% 2052
2022
Q3 		$3.35M Buy
+118,900
New +$2.97M ﹤0.01% 1785

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Citigroup's AMLX Position: Q2 2026 in Review

Citigroup increased its Amylyx Pharmaceuticals (AMLX) stake by 116% in Q2 2026, buying an estimated $571K and bringing the position to 68,684 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #3297.

Citigroup first reported a position in AMLX in Q1 2022 and has held it in 18 quarters since. The position peaked at $5.71M in Q4 2023. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Citigroup held 68,684 shares of Amylyx Pharmaceuticals worth $1.23M as of Q2 2026.
  • Citigroup bought 36,902 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $571K.
  • Amylyx Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3297 holding.
  • Citigroup first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 18 quarters since.
  • Citigroup's Amylyx Pharmaceuticals position peaked at $5.71M in Q4 2023.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.